List of Excipients in Branded Drug NALOXONE HYDROCHLORIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sandoz Inc	NALOXONE HYDROCHLORIDE	naloxone hydrochloride nasal spray	0781-7176	BENZALKONIUM CHLORIDE
Sandoz Inc	NALOXONE HYDROCHLORIDE	naloxone hydrochloride nasal spray	0781-7176	EDETATE DISODIUM
Sandoz Inc	NALOXONE HYDROCHLORIDE	naloxone hydrochloride nasal spray	0781-7176	HYDROCHLORIC ACID
Sandoz Inc	NALOXONE HYDROCHLORIDE	naloxone hydrochloride nasal spray	0781-7176	SODIUM CHLORIDE

Generic Drugs Containing NALOXONE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	naloxone hydrochloride	0093-2165	BENZALKONIUM CHLORIDE
Teva Pharmaceuticals USA Inc	naloxone hydrochloride	0093-2165	EDETATE DISODIUM
Teva Pharmaceuticals USA Inc	naloxone hydrochloride	0093-2165	HYDROCHLORIC ACID
Teva Pharmaceuticals USA Inc	naloxone hydrochloride	0093-2165	SODIUM CHLORIDE

What are the Most Frequently-Used Excipients in NALOXONE HYDROCHLORIDE?

# Of NDCs	Excipient
25	BENZALKONIUM CHLORIDE
25	EDETATE DISODIUM
87	HYDROCHLORIC ACID
16	METHYLPARABEN

Naloxone Hydrochloride Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

Naloxone hydrochloride is a mature, low-cost opioid antagonist with limited active-ingredient differentiation. Commercial value is concentrated in route of administration, dose strength, device usability, shelf stability, access status, and public-sector distribution. The strongest excipient opportunities are nasal products that improve preservative strategy, spray performance, tolerability, container compatibility, and stability without increasing regulatory complexity.

What is the commercial market for naloxone hydrochloride?

Naloxone hydrochloride is marketed primarily as an injectable solution and as a ready-to-use nasal spray. The U.S. market includes prescription products, generic injections, branded nasal sprays, and over-the-counter products.

Product	Company	Route	Strength	U.S. regulatory status
Narcan	Emergent BioSolutions	Nasal spray	4 mg/0.1 mL	OTC approval in 2023
Kloxxado	Hikma Pharmaceuticals	Nasal spray	8 mg/0.1 mL	Prescription
RiVive	Harm Reduction Therapeutics	Nasal spray	3 mg/0.1 mL	OTC approval in 2023
Teva generic naloxone nasal spray	Teva	Nasal spray	4 mg/0.1 mL	Generic prescription product
Zimhi	Adamis Pharmaceuticals, now associated with Sandoz commercialization	Injection	5 mg/0.5 mL	Prescription
Generic naloxone injection	Multiple manufacturers	Intramuscular, intravenous, subcutaneous	Multiple concentrations	ANDA and legacy injectable products

FDA approved the first nonprescription naloxone nasal spray, Narcan, in March 2023. FDA approved RiVive as an OTC nasal spray in July 2023.[1,2] OTC status expands distribution through pharmacies, retail channels, vending machines, schools, workplaces, correctional facilities, and community programs.

The market is less dependent on conventional physician prescribing than most pharmaceutical categories. Procurement contracts, public grants, state programs, emergency medical services, harm-reduction organizations, and price per rescue dose have a greater effect on volume.

Which excipients are used in commercial naloxone products?

Commercial excipient systems are deliberately simple because naloxone hydrochloride is water-soluble and can be formulated as an aqueous solution.

Nasal spray excipient systems

The Narcan 4 mg/0.1 mL formulation contains naloxone hydrochloride, sodium chloride, benzalkonium chloride, disodium edetate, hydrochloric acid, and purified water. Hydrochloric acid adjusts pH. Sodium chloride provides tonicity control. Benzalkonium chloride acts as a preservative, while disodium edetate supports preservative performance and may bind trace metals that catalyze degradation.[3]

Kloxxado uses a comparable aqueous nasal-spray approach with sodium chloride, benzalkonium chloride, disodium edetate, hydrochloric acid, and water.[4] The similarity reflects the technical requirements of a low-volume, multidose-style pump presentation rather than a lack of formulation innovation.

Excipient function	Common material	Commercial purpose	Key development issue
Vehicle	Purified water	Dissolves naloxone hydrochloride	Microbial control and container compatibility
Tonicity agent	Sodium chloride	Reduces nasal irritation and controls osmolality	Excess concentration can increase discomfort
Preservative	Benzalkonium chloride	Controls microbial growth	Potential nasal tolerability and device adsorption concerns
Chelator	Disodium edetate	Binds metal ions and supports stability	Must be justified through impurity and preservative data
pH adjuster	Hydrochloric acid, sometimes sodium hydroxide	Controls chemical stability and comfort	pH affects degradation, solubility, and mucosal tolerability

Injectable excipient systems

Naloxone injection products generally use sodium chloride, water for injection, and pH adjustment with hydrochloric acid or sodium hydroxide. The formulation burden is lower than for nasal delivery because injection products do not require spray plume control or nasal deposition.

Injectable products may use preservatives in multidose presentations, while single-dose presentations can avoid them. The primary formulation risks are particulate control, container closure integrity, sterilization, extractables and leachables, and compatibility with syringes or autoinjector components.

Orally disintegrating and buccal opportunities

Oral naloxone products face a pharmacology problem. Naloxone has substantial first-pass metabolism and is generally more effective when administered parenterally or intranasally. An oral product would require either a buccal or sublingual delivery strategy, higher dosing, a permeation-enhancing system, or a combination approach.

Potential excipient classes include:

• Mannitol, lactose, or isomalt for orally disintegrating tablets.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Mucoadhesive polymers such as hydroxypropyl cellulose or carbomers.
• Permeation enhancers for buccal absorption.
• Taste-masking agents and sweeteners.
• Solubilizers or pH modifiers.

These products carry greater clinical and regulatory risk than nasal sprays. Naloxone must reach systemic circulation rapidly enough to reverse opioid-induced respiratory depression. A convenient dosage form that produces inconsistent or delayed exposure has limited commercial value.

What excipient strategy best supports a new naloxone nasal spray?

The most defensible strategy is a low-complexity, preservative-controlled aqueous formulation paired with a reliable unit-dose pump.

Strategy 1: Use an established excipient platform

A formulation based on sodium chloride, water, pH adjustment, benzalkonium chloride, and disodium edetate has several advantages:

• Familiar safety profile.
• Established regulatory precedent.
• Straightforward analytical methods.
• Low cost of goods.
• Broad availability from excipient suppliers.
• Reduced clinical-development burden.

The limitation is weak differentiation. A near-copy formulation is likely to compete mainly on price, procurement access, device performance, and regulatory timing.

Strategy 2: Develop a preservative-free unit-dose product

A preservative-free nasal spray could use a sealed unit-dose container or a device with a validated microbial barrier. The commercial rationale is reduced concern about repeated nasal exposure to benzalkonium chloride and improved positioning for pediatric, chronic-risk, institutional, or frequent-use settings.

The formulation would need to demonstrate:

• Microbiological integrity through shelf life.
• Consistent delivered dose.
• Container closure integrity.
• Low extractables and leachables.
• Compatibility with the pump and actuator.
• Stability after temperature excursions.
• No meaningful adsorption of naloxone to device components.

A preservative-free system may improve product positioning but increase device cost and packaging complexity. It is more attractive where procurement buyers value tolerability and product quality over the lowest unit price.

Strategy 3: Optimize pH and nasal tolerability

Naloxone hydrochloride is acidic in aqueous solution. Product developers can evaluate pH adjustment within the stability and tolerability window. The target should balance:

• Chemical stability.
• Naloxone solubility.
• Nasal comfort.
• Spray plume behavior.
• Device material compatibility.
• Absorption consistency.

A buffered system may improve pH control but can increase ionic strength and formulation complexity. Strong buffering is not automatically preferable because the nasal cavity has limited tolerance for acidic or highly ionic formulations.

Strategy 4: Engineer the excipient-device combination

For nasal naloxone, the device is part of the drug product. Excipient selection affects:

• Pump priming.
• Delivered volume.
• Droplet-size distribution.
• Plume geometry.
• Actuator clogging.
• Dose uniformity.
• Adsorption to elastomers and plastics.
• Stability under freezing and heat exposure.

A formulation that is chemically stable in glass may perform differently in a polypropylene, polyethylene, cyclic olefin polymer, or elastomer-containing pump. Device screening should occur early, not after formulation selection.

What formulation patents protect naloxone products?

Naloxone hydrochloride itself is a long-established generic active ingredient. The strongest intellectual-property positions are more likely to concern nasal delivery systems, pump assemblies, formulation parameters, preservative systems, packaging, and methods of use than the molecule.

IP category	Potential claim focus	Commercial relevance
Formulation	pH, concentration, osmolality, preservative, chelator, stabilizer	May differentiate a nasal solution but can be vulnerable to design-around
Device	Pump geometry, actuator, unit-dose package, tamper evidence	Often important for delivered-dose consistency
Method of use	Repeated dosing, community administration, opioid overdose treatment	May affect labeling and generic carve-outs
Packaging	Unit-dose container, barrier system, temperature protection	Can protect product configuration
Manufacturing	Filling, sterilization, assembly, device integration	May create process barriers but rarely blocks all generic entry
Combination product	Drug-device relationship and performance specifications	Can increase development and regulatory complexity

The Orange Book and FDA product-specific guidance should be reviewed for each listed nasal spray and injection product before relying on a patent-based market-entry assumption. Naloxone has no meaningful new-molecular-entity exclusivity remaining. Market protection is therefore primarily patent-based, regulatory, contractual, or operational.

How strong is the patent estate for naloxone nasal sprays?

The estate is likely to be narrower than the commercial opportunity. A formulation that uses conventional excipients at conventional concentrations may be difficult to protect broadly. Stronger claims would need a measurable technical distinction, such as:

• A specific preservative-free architecture.
• A defined delivered-dose profile.
• A device and formulation combination that improves plume performance.
• Stability under extreme temperature conditions.
• Reduced nasal irritation with maintained systemic exposure.
• A non-obvious excipient ratio linked to a demonstrated technical effect.

Patent applicants should avoid relying solely on routine choices of sodium chloride, benzalkonium chloride, EDTA, or hydrochloric acid. Those elements appear in established products and may face novelty or obviousness challenges.

When does naloxone lose exclusivity, and what generic-entry risks exist?

Naloxone’s active-moiety exclusivity has long expired. Generic entry is already established for injectable products and has reached nasal spray products.

Generic entry scenarios

Scenario	Likely competitive effect
Additional 4 mg nasal sprays	Price pressure on Narcan and other 4 mg products
8 mg generic nasal spray	Direct competition with Kloxxado
Preservative-free nasal spray	Premium or institutional niche if tolerability is demonstrated
Lower-cost 3 mg nasal spray	Competition with RiVive and public-sector procurement
Generic autoinjector	High technical and device-development burden
Ready-to-use prefilled syringe	Moderate differentiation, with sterility and usability requirements
Hospital injectable products	Continued price competition and supply-contract pressure

A Paragraph IV challenge could target patents listed for a branded nasal spray or injection. The practical risk depends on the exact Orange Book entries, patent claims, filing date, ANDA certification, and whether the brand has sued within the statutory period. A generic company can also pursue a Paragraph III certification, a section viii labeling carve-out, or a product design that avoids patented method-of-use claims.

Because naloxone is widely used in emergency and public-health settings, a generic entrant may receive strong purchasing support even with modest differentiation. The highest-volume opportunities are likely to be products that combine reliable supply with lower acquisition cost.

What is the FDA regulatory status of naloxone products?

FDA has established regulatory precedent for injectable naloxone and nasal-spray naloxone. The main pathways are:

• ANDA for a generic product that matches a reference listed drug.
• NDA or 505(b)(2) for a product with a differentiated device, formulation, strength, or route.
• OTC switch application supported by consumer-label comprehension, self-selection, and actual-use data where required.
• Supplemental NDA for certain changes to an approved product.

An OTC naloxone product must support safe use without professional supervision. Packaging, instructions, symptom recognition, repeat dosing directions, and emergency-call instructions are central to approval and commercialization.

The OTC switch changes market access but does not eliminate the need to demonstrate product quality. The applicant must still control delivered dose, spray performance, stability, microbiological quality, and human-factors performance.

Which companies are competing in naloxone hydrochloride?

Emergent BioSolutions has the strongest consumer-recognition position through Narcan. Hikma competes with Kloxxado and has an established injectable portfolio. Teva has generic nasal-spray capabilities. Harm Reduction Therapeutics competes through RiVive, an OTC product developed with a public-health access model. Multiple generic manufacturers compete in injectable naloxone.

Competitive comparison

Company/product	Primary advantage	Main vulnerability
Emergent/Narcan	Brand recognition, OTC availability, broad channel presence	Price pressure and generic substitution
Hikma/Kloxxado	High-dose nasal product and generic-injectable infrastructure	Prescription status may limit some channels
Teva generic	Generic pricing and established regulatory infrastructure	Limited brand differentiation
HRT/RiVive	OTC access and public-health positioning	Smaller commercial infrastructure
Generic injectables	Low cost and hospital familiarity	Supply-chain and margin pressure

What licensing and partnership opportunities exist?

The most attractive licensing opportunities are not based on naloxone hydrochloride alone. They involve formulation, device, manufacturing, access, or distribution assets.

Excipient and formulation licensing

An excipient supplier or drug-delivery company could license:

• A preservative-free nasal platform.
• A low-irritation nasal formulation.
• A temperature-stable formulation for field deployment.
• A pump compatible with high-viscosity or low-volume solutions.
• A unit-dose container with strong microbial protection.
• A bioadhesive or rapid-absorption system.
• A stable formulation for prefilled syringes or autoinjectors.

The licensor must demonstrate a technical advantage through comparative data. A novel excipient without a clear benefit is unlikely to justify a royalty-bearing deal in a low-cost generic market.

Distribution and public-sector partnerships

Commercial value can come from contracts with:

• State opioid-response programs.
• Pharmacies and pharmacy benefit organizations.
• Emergency medical services.
• Universities and schools.
• Correctional systems.
• Employers and industrial sites.
• Shelters and harm-reduction organizations.
• Federal and municipal procurement agencies.

For naloxone, channel access can be more valuable than a narrow formulation patent. A supplier that can provide reliable inventory, simple training materials, and favorable pricing may win contracts despite limited IP protection.

What manufacturing and IP barriers affect market entry?

Naloxone API is widely available and is not the principal barrier. The more relevant barriers are:

1. Nasal pump qualification and dose uniformity.
2. Human-factors validation for emergency use.
3. Container closure integrity.
4. Stability under heat, cold, and transportation stress.
5. Extractables and leachables.
6. Assembly and filling at commercial scale.
7. OTC labeling and packaging.
8. Public-sector procurement qualification.
9. Patent clearance for the device and product configuration.
10. Reliable supply during demand surges.

The manufacturing model should minimize specialized components. A proprietary pump may improve protection but increase single-source risk. A standard pump may lower cost but reduce differentiation and increase freedom-to-operate exposure.

How does naloxone compare with other emergency drug products?

Naloxone has a lower API barrier than epinephrine autoinjectors but a higher access and deployment burden than conventional injectable generics. Compared with epinephrine, naloxone has greater public-sector and community-distribution potential because nonprofessionals routinely administer it. Compared with injectable naloxone, nasal naloxone has higher device and packaging costs but a broader user base.

Attribute	Naloxone nasal spray	Naloxone injection	Epinephrine autoinjector
API differentiation	Low	Low	Low
Device complexity	Moderate	Low to moderate	High
OTC potential	Established	Limited	Established for some products
Excipient opportunity	Moderate	Low	Moderate
Public access opportunity	High	Lower	Moderate
Generic price risk	High	Very high	High
Human-factors burden	High	Moderate	High

What revenue exposure does the patent and excipient strategy create?

Brand revenue is exposed to generic nasal sprays, OTC price competition, government purchasing pressure, and substitution among 3 mg, 4 mg, and 8 mg products. Excipient suppliers have more stable exposure if they sell standardized materials across multiple naloxone manufacturers, but margins may be limited.

The best commercial returns are likely to come from:

• A preservative-free product with clear tolerability evidence.
• A low-cost, high-throughput OTC nasal spray.
• A device platform usable for multiple emergency drugs.
• A temperature-stable product designed for field storage.
• A contract-manufacturing package combining formulation, filling, pump assembly, and regulatory support.
• A public-sector supply agreement with predictable volume.

A standalone excipient patent is less attractive than a drug-device combination with validated performance and a practical manufacturing route.

Key Takeaways

• Naloxone hydrochloride is a mature active ingredient with no meaningful remaining molecule-level exclusivity.
• Commercial differentiation is concentrated in nasal delivery, device performance, OTC access, stability, tolerability, and supply reliability.
• Conventional excipients such as sodium chloride, benzalkonium chloride, disodium edetate, hydrochloric acid, and purified water support low-cost products but provide limited patent strength.
• Preservative-free unit-dose nasal sprays are the clearest formulation opportunity.
• The most important technical work involves formulation-device compatibility, delivered-dose uniformity, temperature stability, and microbial control.
• Generic and OTC competition creates substantial price pressure.
• Licensing value is strongest for integrated formulation, device, manufacturing, and distribution packages.
• Naloxone has no biosimilar risk because it is a chemically synthesized small molecule.
• Orange Book patent and exclusivity analysis must be performed product by product because protection depends on the listed product, device, formulation, and labeling claims.

FAQs

Can benzalkonium chloride be removed from a naloxone nasal spray?

Yes. A preservative-free product can use a sealed unit-dose container or a validated microbial-barrier device. The applicant must establish sterility or microbial integrity, stability, dose uniformity, and container compatibility.

Is sodium chloride essential in naloxone nasal spray?

No. Sodium chloride is commonly used to control tonicity, but other tonicity agents may be evaluated. Any substitute must maintain nasal tolerability, stability, spray performance, and regulatory acceptability.

Can a new naloxone formulation obtain a patent?

Yes, but broad protection is difficult because the active ingredient and common aqueous excipients are well established. Patentability is stronger when a formulation-device combination produces a demonstrated technical effect.

Are naloxone nasal sprays eligible for automatic generic substitution?

Substitution depends on FDA approval, therapeutic-equivalence ratings, state law, payer policy, and the specific reference listed drug. OTC products may follow different retail and substitution dynamics than prescription products.

Is a temperature-stable naloxone product commercially valuable?

Yes. Naloxone is frequently stored in vehicles, outdoor cabinets, schools, workplaces, and community locations. Improved stability under heat and freezing conditions could support premium positioning, institutional contracts, and reduced product loss.

References

1. U.S. Food and Drug Administration. (2023, March 29). FDA approves first over-the-counter naloxone nasal spray. https://www.fda.gov/news-events/press-announcements/fda-approves-first-over-counter-naloxone-nasal-spray

2. U.S. Food and Drug Administration. (2023, July 28). FDA approves second over-the-counter naloxone nasal spray. https://www.fda.gov/news-events/press-announcements/fda-approves-second-over-counter-naloxone-nasal-spray

3. Emergent BioSolutions. (2023). Narcan naloxone hydrochloride nasal spray prescribing information. U.S. Food and Drug Administration.

4. Hikma Pharmaceuticals. (2021). Kloxxado naloxone hydrochloride nasal spray prescribing information. U.S. Food and Drug Administration.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

6. Centers for Disease Control and Prevention. (2024). Understanding the opioid overdose epidemic. https://www.cdc.gov/overdose-prevention/about/index.html